Resource Type: Blog

Part one of this four-part series looked at how host, tumor, and environmental factors shape tumor-immune system interactions. In the next few blogs, we will consider how each of these…

President Jimmy Carter announced this spring that he no longer needed treatments for the metastatic melanoma found in his brain–after treatment with pembrolizumab (Keytruda, Merck), his physicians could no longer…

[caption id="attachment_146" align="alignright" width="300"] NanoString at ASH 2016.[/caption] We attended the annual meeting of the American Society of Hematology (ASH) in San Diego. The convention center was abuzz with scientists…

What do we already know about tumor-immune system interactions, and how can this information be used to help guide us toward the best therapeutic choice? That is exactly the question…

Looking beyond anti-PD1/PDL1 with combination therapy and gene signature testing

Immuno-oncology (IO) focuses on harnessing the tremendous power of the human immune system to detect and destroy cancer cells.